Amarin | AMRN - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 1000K 2026-06
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amarin USD 51.48M 113K 2025-12
AstraZeneca USD 12.22B 4.04B 2026-06
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
DBV Technologies USD 47.9M 2.2M 2026-03
GlaxoSmithKline GBP 5.8B 468M 2026-06
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novartis USD 10.2B 912M 2026-06